Compounded incretins in clinical practice: An opinion of the endocrine and metabolism practice and research network of the American College of Clinical Pharmacy.

Document Type

Article

Publication Date

9-1-2025

Abstract

AIMS: This article aims to summarize the role of compounded incretin mimetics in clinical practice and in the context of drug shortages.

METHODS: The Endocrine and Metabolism Practice and Research Network, a focused group of the American College of Clinical Pharmacy members, convened an independent committee to evaluate the role of compounded incretin mimetics.

RESULTS: There is limited data demonstrating positive clinical outcomes in small cohorts of patients receiving compounded semaglutide and tirzepatide. However, there remain significant legal and safety concerns since compounded incretins do not undergo approval by the Food and Drug Administration.

CONCLUSION: Whenever possible, healthcare providers should make every effort to assist patients with obtaining approved medications. If patients choose to obtain compounded incretins, providers can encourage safety by ensuring use of reputable compounding pharmacies and routinely monitoring patients for safety and efficacy of the compounded product.

Publication Title

Diabetes and Metabolic Syndrome

Volume

19

Issue

9

PubMed ID

41176849

Comments

This article was published in Diabetes & Metabolic Syndrome, Volume 19, Issue 9.

The published version is available at https://doi.org/10.1016/j.dsx.2025.103314.

Copyright © 2025 Research Trust of DiabetesIndia (DiabetesIndia) and National Diabetes Obesity and Cholesterol Foundation (N-DOC).

This document is currently not available here.

COinS